Biohaven Ltd. (BHVN) Financial Statements
Industry: Pharmaceutical Preparations
In fiscal 2025, Biohaven reported revenue of $0. Net income was -$738.8M, or -$6.86 per diluted share. Operating activities generated -$609.4M of cash, leaving -$610.2M of free cash flow. At fiscal year end, Biohaven held $451.4M in total assets against $399.4M in total liabilities, including $230.0M of cash and equivalents.
Open the full interactive Biohaven financials → Quarterly statements, key ratios, valuation history and price charts.
Biohaven Key Stats
| Share Price | $11.42 |
|---|---|
| Market Cap | $1.72B |
| 52-Week Range | $7.79 – $18.11 |
| Shares Outstanding | 150.6 million (basic, 2026 Q2) |
Biohaven Income Statement
| FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Operating Income | -$567.9M | -$436.1M | -$885.1M | -$745.4M |
| Pre-Tax Income | -$569.8M | -$409.6M | -$845.7M | -$737.4M |
| Income Tax | $438,000 | -$1.4M | $735,000 | $1.4M |
| Net Income | -$570.3M | -$408.2M | -$846.4M | -$738.8M |
| Diluted EPS | -$12.75 | -$5.73 | -$9.28 | -$6.86 |
Biohaven Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Net Income | -$173.4M | -$145.6M | -$130.5M | -$137.3M |
| Diluted EPS | -$1.64 | -$1.35 | -$0.88 | -$0.91 |
Biohaven Balance Sheet
| FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|
| Cash & Equivalents | $204.9M | $248.4M | $99.1M | $230.0M |
| Current Assets | $587.0M | $442.4M | $538.5M | $368.3M |
| Total Assets | $661.8M | $513.2M | $615.1M | $451.4M |
| Current Liabilities | $90.0M | $55.4M | $154.2M | $115.9M |
| Total Long-Term Debt | — | — | — | $238.9M |
| Total Liabilities | $123.0M | $85.2M | $191.7M | $399.4M |
| Shareholders' Equity | $538.8M | $428.0M | $423.4M | $52.1M |
Biohaven Cash Flow Statement
| FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|
| Cash From Operations | -$297.7M | -$331.7M | -$582.5M | -$609.4M |
| Cash From Investing | -$304.8M | $129.8M | -$245.0M | $300.6M |
| Cash From Financing | $767.6M | $211.9M | $677.8M | $439.1M |
| Free Cash Flow | -$303.8M | -$334.8M | -$586.5M | -$610.2M |
Figures from Biohaven's 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Biohaven financials page for every line item.
Biohaven Company Profile
| Ticker | BHVN |
|---|---|
| Exchange | NYSE |
| Industry | Pharmaceutical Preparations |
| Headquarters | New Haven, Connecticut |
| Fiscal Year End | December 31 |
| SEC Filer Category | Large accelerated filer |
| SEC CIK | 0001935979 |
Frequently Asked Questions
What was Biohaven's revenue in fiscal 2025?
Biohaven (BHVN) reported revenue of $0 for fiscal 2025.
What is Biohaven's annual revenue history?
Biohaven's annual revenue by fiscal year: 2022: $0; 2023: $0; 2024: $0; 2025: $0.
What was Biohaven's net income in fiscal 2025?
Biohaven reported net income of -$738.8M for fiscal 2025.
What was Biohaven's earnings per share (EPS) in fiscal 2025?
Biohaven's diluted EPS was -$6.86 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did Biohaven generate in fiscal 2025?
Biohaven generated -$610.2M of free cash flow in fiscal 2025.
What was Biohaven's revenue last quarter?
In its most recent reported quarter (2026 Q2), Biohaven reported revenue of $0.
How much debt does Biohaven have?
Biohaven reported $238.9M of long-term debt, including the current portion, at the end of fiscal 2025.
How many shares of Biohaven are outstanding?
Biohaven reported a weighted average of 150.6 million basic shares outstanding in 2026 Q2.
What is Biohaven's market cap?
Based on its latest closing price, Biohaven (BHVN) has a market capitalization of about $1.72B.
When does Biohaven's fiscal year end?
Biohaven's fiscal year end, as registered with the SEC, is December 31.
Where is Biohaven headquartered?
Biohaven lists its business address in New Haven, Connecticut in its SEC filings.